Bain Capital entered a deal to acquire Mitsubishi Tanabe Pharma Corporation (MTPC) from Mitsubishi Chemical Group for 510 ...

The investment firm is acquiring Mitsubishi Tanabe Pharma in a deal valued at $3.3 billion. Elsewhere, Bausch + Lomb hasn’t yet found a suitor and a pair of biotechs cut staff.

I Mitsubishi Chemical Group Corporation (MCG) hereby announces that it has resolved, at a meeting of the Board of Directors held today, to ...

Private equity firm Bain Capital agreed to acquire Mitsubishi Chemical Group’s pharmaceutical unit, adding to a dealmaking ...

US investment group Bain Capital has agreed to buy Mitsubishi Tanabe Pharma for JPY 510 billion (around $3.4 billion), ...

Bain Capital has agreed to acquire Tanabe Pharma, the pharma arm of Mitsubishi Chemical Group Corporation. The deal puts Tanabe Pharma at a valuation of about $3.3 billion. Founded in 1678, Tanabe ...

Bain is laying out 510 billion Japanese yen ($3.3 billion) to acquire Tanabe Pharma in a carve-out transaction from its ...

Mitsubishi UFJ Morgan Stanley Securities and BofA Securities are serving as financial advisors, and Morrison Foerster, Mori, Hamada & Matsumoto and Ropes & Gray are serving as legal advisors to Bain ...

Bain Capital has agreed to acquire Mitsubishi Chemical Group's pharmaceutical business for more than $3 billion, a deal that would allow the Japanese company to focus on its key chemical businesses.

Private equity firm Bain Capital (BCSF) is paying $3.4 billion to buy a 350-year-old Japanese drugs group fighting diabetes ...

TOKYO -- Japan's Mitsubishi Chemical Group announced on Friday the agreed sale of its pharmaceutical subsidiary, Mitsubishi Tanabe Pharma, to U.S. investment fund Bain Capital for approximately 510 ...